Proper technique for administration of ATX-101 (Deoxycholic Acid Injection): Insights from an injection practicum and roundtable discussion

Derek H. Jones, Jeffrey M. Kenkel, Steven Fagien, Dee Anna Glaser, Gary D. Monheit, Karen Stauffer, Jonathan M Sykes

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

ATX-101 (deoxycholic acid injection; Kybella in the United States and Belkyra in Canada; Kythera Biopharmaceuticals, Inc., Westlake Village, CA [an affiliate of Allergan plc, Dublin, Ireland]) is the first aesthetic injectable approved for reduction of submental fat. In February 2014, an injection practicum was conducted in the anatomy laboratory at the University of Texas SouthwesternMedical Center to explore the proper injection technique for ATX-101 and the importance of its appropriate, safe anatomical placement within the submental area. Subsequent to the injection practicum, a structured roundtable discussion was conducted in which potential implications of the various injection protocols evaluated during the practicum were reviewed. Furthermore, the faculty had the opportunity to provide additional perspectives based on their clinical experience with facial injectables and ATX-101 specifically. In this article, the findings from the injection practicum and roundtable discussion are reported.

Original languageEnglish (US)
Pages (from-to)S275-S281
JournalDermatologic Surgery
Volume42
DOIs
StatePublished - 2016

Fingerprint

Deoxycholic Acid
Injections
Esthetics
Ireland
Canada
Anatomy
Fats

ASJC Scopus subject areas

  • Surgery
  • Dermatology

Cite this

Proper technique for administration of ATX-101 (Deoxycholic Acid Injection) : Insights from an injection practicum and roundtable discussion. / Jones, Derek H.; Kenkel, Jeffrey M.; Fagien, Steven; Glaser, Dee Anna; Monheit, Gary D.; Stauffer, Karen; Sykes, Jonathan M.

In: Dermatologic Surgery, Vol. 42, 2016, p. S275-S281.

Research output: Contribution to journalArticle

Jones, Derek H. ; Kenkel, Jeffrey M. ; Fagien, Steven ; Glaser, Dee Anna ; Monheit, Gary D. ; Stauffer, Karen ; Sykes, Jonathan M. / Proper technique for administration of ATX-101 (Deoxycholic Acid Injection) : Insights from an injection practicum and roundtable discussion. In: Dermatologic Surgery. 2016 ; Vol. 42. pp. S275-S281.
@article{8e328edad36841279150ff180aeaf32d,
title = "Proper technique for administration of ATX-101 (Deoxycholic Acid Injection): Insights from an injection practicum and roundtable discussion",
abstract = "ATX-101 (deoxycholic acid injection; Kybella in the United States and Belkyra in Canada; Kythera Biopharmaceuticals, Inc., Westlake Village, CA [an affiliate of Allergan plc, Dublin, Ireland]) is the first aesthetic injectable approved for reduction of submental fat. In February 2014, an injection practicum was conducted in the anatomy laboratory at the University of Texas SouthwesternMedical Center to explore the proper injection technique for ATX-101 and the importance of its appropriate, safe anatomical placement within the submental area. Subsequent to the injection practicum, a structured roundtable discussion was conducted in which potential implications of the various injection protocols evaluated during the practicum were reviewed. Furthermore, the faculty had the opportunity to provide additional perspectives based on their clinical experience with facial injectables and ATX-101 specifically. In this article, the findings from the injection practicum and roundtable discussion are reported.",
author = "Jones, {Derek H.} and Kenkel, {Jeffrey M.} and Steven Fagien and Glaser, {Dee Anna} and Monheit, {Gary D.} and Karen Stauffer and Sykes, {Jonathan M}",
year = "2016",
doi = "10.1097/DSS.0000000000000875",
language = "English (US)",
volume = "42",
pages = "S275--S281",
journal = "Dermatologic Surgery",
issn = "1076-0512",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Proper technique for administration of ATX-101 (Deoxycholic Acid Injection)

T2 - Insights from an injection practicum and roundtable discussion

AU - Jones, Derek H.

AU - Kenkel, Jeffrey M.

AU - Fagien, Steven

AU - Glaser, Dee Anna

AU - Monheit, Gary D.

AU - Stauffer, Karen

AU - Sykes, Jonathan M

PY - 2016

Y1 - 2016

N2 - ATX-101 (deoxycholic acid injection; Kybella in the United States and Belkyra in Canada; Kythera Biopharmaceuticals, Inc., Westlake Village, CA [an affiliate of Allergan plc, Dublin, Ireland]) is the first aesthetic injectable approved for reduction of submental fat. In February 2014, an injection practicum was conducted in the anatomy laboratory at the University of Texas SouthwesternMedical Center to explore the proper injection technique for ATX-101 and the importance of its appropriate, safe anatomical placement within the submental area. Subsequent to the injection practicum, a structured roundtable discussion was conducted in which potential implications of the various injection protocols evaluated during the practicum were reviewed. Furthermore, the faculty had the opportunity to provide additional perspectives based on their clinical experience with facial injectables and ATX-101 specifically. In this article, the findings from the injection practicum and roundtable discussion are reported.

AB - ATX-101 (deoxycholic acid injection; Kybella in the United States and Belkyra in Canada; Kythera Biopharmaceuticals, Inc., Westlake Village, CA [an affiliate of Allergan plc, Dublin, Ireland]) is the first aesthetic injectable approved for reduction of submental fat. In February 2014, an injection practicum was conducted in the anatomy laboratory at the University of Texas SouthwesternMedical Center to explore the proper injection technique for ATX-101 and the importance of its appropriate, safe anatomical placement within the submental area. Subsequent to the injection practicum, a structured roundtable discussion was conducted in which potential implications of the various injection protocols evaluated during the practicum were reviewed. Furthermore, the faculty had the opportunity to provide additional perspectives based on their clinical experience with facial injectables and ATX-101 specifically. In this article, the findings from the injection practicum and roundtable discussion are reported.

UR - http://www.scopus.com/inward/record.url?scp=85014881298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014881298&partnerID=8YFLogxK

U2 - 10.1097/DSS.0000000000000875

DO - 10.1097/DSS.0000000000000875

M3 - Article

C2 - 27787267

AN - SCOPUS:85014881298

VL - 42

SP - S275-S281

JO - Dermatologic Surgery

JF - Dermatologic Surgery

SN - 1076-0512

ER -